More about

Crohn's Disease

News
June 04, 2024
5 min watch
Save

VIDEO: ‘Compelling data’ from VIVID-1 study support use of mirikizumab in Crohn’s disease

VIDEO: ‘Compelling data’ from VIVID-1 study support use of mirikizumab in Crohn’s disease

WASHINGTON — In this video, Mark Genovese, MD, discusses results of the VIVID-1 study, in which mirikizumab demonstrated noninferiority to ustekinumab for week 52 clinical remission among patients with moderate to severe Crohn’s disease.

News
June 03, 2024
2 min read
Save

A catered low-fat, high-fiber diet ‘new, hopeful option’ to manage Crohn’s disease

A catered low-fat, high-fiber diet ‘new, hopeful option’ to manage Crohn’s disease

WASHINGTON — Patients with Crohn’s disease who ate a catered low-fat, high-fiber diet for 8 weeks experienced improvements in symptoms, inflammation and quality of life vs. those offered counseling alone, researchers reported.

News
May 31, 2024
2 min read
Save

Entyvio effective in pediatric IBD, ‘should be included in our treatment paradigm’

Entyvio effective in pediatric IBD, ‘should be included in our treatment paradigm’

WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher.

News
May 30, 2024
2 min read
Save

‘Unexpectedly high’ placebo response derails darvadstrocel for Crohn’s perianal fistulas

‘Unexpectedly high’ placebo response derails darvadstrocel for Crohn’s perianal fistulas

WASHINGTON — Darvadstrocel demonstrated “no statistically significant or clinically meaningful” benefit vs. placebo for complex perianal fistulas and Crohn’s disease, according to ADMIRE-CD II trial data presented at Digestive Disease Week.

News
May 23, 2024
1 min read
Save

Simlandi launches in U.S. as third interchangeable Humira biosimilar

Simlandi launches in U.S. as third interchangeable Humira biosimilar

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.

News
May 21, 2024
2 min read
Save

SEQUENCE: Skyrizi outperforms for Crohn’s remission; Stelara ‘still remains on the table’

SEQUENCE: Skyrizi outperforms for Crohn’s remission; Stelara ‘still remains on the table’

WASHINGTON — Although a greater number of patients with Crohn’s disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara, choosing between the two therapies “still remains on the table,” a researcher noted.

News
May 21, 2024
2 min read
Save

Statin use linked to ‘sharp 86% risk reduction’ for primary sclerosing cholangitis in IBD

Statin use linked to ‘sharp 86% risk reduction’ for primary sclerosing cholangitis in IBD

WASHINGTON — Statin use was associated with up to a 90% risk reduction for new-onset primary sclerosing cholangitis among patients with inflammatory bowel disease, according to data presented at Digestive Disease Week.

News
May 08, 2024
3 min read
Save

Low anti-TNF concentrations at week 14 linked to long-term loss of response in Crohn’s

Low anti-TNF concentrations at week 14 linked to long-term loss of response in Crohn’s

Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes.

News
May 02, 2024
1 min read
Save

FDA warns of ‘rare risk’ for thiopurine-related intrahepatic cholestasis of pregnancy

FDA warns of ‘rare risk’ for thiopurine-related intrahepatic cholestasis of pregnancy

The FDA has issued a safety alert warning patients and health care providers of a “rare risk of intrahepatic cholestasis of pregnancy” linked to thiopurine use.

News
May 01, 2024
2 min read
Save

FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo

FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo

The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.

View more